FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 338:784-791 March 19, 1998 Number 12 Next

	Full Text PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Endothelin is a powerful vasoconstrictor peptide derived from the endothelium. We evaluated the contribution of endothelin to blood-pressure regulation in patients with essential hypertension by studying the effect of an endothelin-receptor antagonist, bosentan.

Methods We studied 293 patients with mild-to-moderate essential hypertension. After a placebo run-in period of four to six weeks, patients were randomly assigned to receive one of four oral doses of bosentan (100, 500, or 1000 mg once daily or 1000 mg twice daily), placebo, or the angiotensin-converting–enzyme inhibitor enalapril (20 mg once daily) for four weeks. Blood pressure was measured before and after treatment.

Results As compared with placebo, bosentan resulted in a significant reduction in diastolic pressure with a daily dose of 500 or 2000 mg (an absolute reduction of 5.7 mm Hg at each dose), which was similar to the reduction with enalapril (5.8 mm Hg). There were no significant changes in heart rate. Bosentan did not result in activation of the sympathetic nervous system (as determined by measurement of the plasma norepinephrine level) or the renin–angiotensin system (as determined by measurements of plasma renin activity and angiotensin II levels).

Conclusions An endothelin-receptor antagonist, bosentan, significantly lowered blood pressure in patients with essential hypertension, suggesting that endothelin may contribute to elevated blood pressure in such patients. The favorable effect of treatment with bosentan on blood pressure occurred without reflexive neurohormonal activation.

Source Information

From the Clinical Pharmacology Unit, Monash University and Alfred Hospital, Prahran, Victoria, Australia (H.K.); the Department of Medicine, Barzilai Medical Center, Ashkelon, Israel (R.J.V.); the Hypertension Research Unit, Centre Hospitalier Universitaire de Quebec, Ste.-Foy, Que., Canada (Y.L.); and Hoffmann–LaRoche, Basel, Switzerland (M.B., V.C.).

Address reprint requests to Dr. Krum at the Clinical Pharmacology Unit, Monash University, Alfred Hospital, Prahran, Victoria 3181, Australia.

Full Text of this Article

Related Letters:

Bosentan in Essential Hypertension
Haynes W. G., Ferro C. J., Webb D. J., Krämer B. K., Schweda F., Riegger G. A.J., Krum H., Lacourciere Y., Charlon V.
Extract | Full Text  
N Engl J Med 1998; 339:346-347, Jul 30, 1998. Correspondence

This article has been cited by other articles:

• Dhaun, N., Ferro, C. J., Davenport, A. P., Haynes, W. G., Goddard, J., Webb, D. J. (2007). Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease. Nephrol Dial Transplant 22: 3228-3234 [Abstract] [Full Text]  
• Bussemaker, E., Pistrosch, F., Forster, S., Herbrig, K., Gross, P., Passauer, J., Brandes, R. P. (2007). Rho kinase contributes to basal vascular tone in humans: role of endothelium-derived nitric oxide. Am. J. Physiol. Heart Circ. Physiol. 293: H541-H547 [Abstract] [Full Text]  
• Quaschning, T., Voss, F., Relle, K., Kalk, P., Vignon-Zellweger, N., Pfab, T., Bauer, C., Theilig, F., Bachmann, S., Kraemer-Guth, A., Wanner, C., Theuring, F., Galle, J., Hocher, B. (2007). Lack of Endothelial Nitric Oxide Synthase Promotes Endothelin-Induced Hypertension: Lessons from Endothelin-1 Transgenic/Endothelial Nitric Oxide Synthase Knockout Mice. J. Am. Soc. Nephrol. 18: 730-740 [Abstract] [Full Text]  
• Feletou, M., Vanhoutte, P. M. (2006). Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am. J. Physiol. Heart Circ. Physiol. 291: H985-H1002 [Abstract] [Full Text]  
• ROSSI, G. P., PITTER, G. (2006). Genetic Variation in the Endothelin System: Do Polymorphisms Affect the Therapeutic Strategies?. Ann. N. Y. Acad. Sci. 1069: 34-50 [Abstract] [Full Text]  
• Dhaun, N., Goddard, J., Webb, DavidJ. (2006). The Endothelin System and Its Antagonism in Chronic Kidney Disease. J. Am. Soc. Nephrol. 17: 943-955 [Abstract] [Full Text]  
• Leslie, S J, Spratt, J C S, McKee, S P, Strachan, F E, Newby, D E, Northridge, D B, Denvir, M A, Webb, D J (2005). Direct comparison of selective endothelin A and non-selective endothelin A/B receptor blockade in chronic heart failure. Heart 91: 914-919 [Abstract] [Full Text]  
• Attina, T, Camidge, R, Newby, D E, Webb, D J (2005). Endothelin antagonism in pulmonary hypertension, heart failure, and beyond. Heart 91: 825-831 [Full Text]  
• Reisbig, K. A, Coffman, P. A, Floreani, A. A, Bultsma, C. J, Olsen, K. M (2005). Staggered Transition to Epoprostenol from Treprostinil in Pulmonary Arterial Hypertension. The Annals of Pharmacotherapy 39: 739-743 [Abstract] [Full Text]  
• Multani, M. M., Ikonomidis, J. S., Kim, P. Y., Miller, E. A., Payne, K. J., Mukherjee, R., Dorman, B. H., Spinale, F. G. (2005). Dynamic and differential changes in myocardial and plasma endothelin in patients undergoing cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg. 129: 584-590 [Abstract] [Full Text]  
• Kowala, M. C., Murugesan, N., Tellew, J., Carlson, K., Monshizadegan, H., Ryan, C., Gu, Z., Kane, B., Fadnis, L., Baska, R. A., Beyer, S., Arthur, S., Dickinson, K., Zhang, D., Perrone, M., Ferrer, P., Giancarli, M., Baumann, J., Bird, E., Panchal, B., Yang, Y., Trippodo, N., Barrish, J., Macor, J. E. (2004). Novel Dual Action AT1 and ETA Receptor Antagonists Reduce Blood Pressure in Experimental Hypertension. J. Pharmacol. Exp. Ther. 309: 275-284 [Abstract] [Full Text]  
• Goddard, J., Johnston, N. R., Hand, M. F., Cumming, A. D., Rabelink, T. J., Rankin, A. J., Webb, D. J. (2004). Endothelin-A Receptor Antagonism Reduces Blood Pressure and Increases Renal Blood Flow in Hypertensive Patients With Chronic Renal Failure: A Comparison of Selective and Combined Endothelin Receptor Blockade. Circulation 109: 1186-1193 [Abstract] [Full Text]  
• Oparil, S., Zaman, M. A., Calhoun, D. A. (2003). Pathogenesis of Hypertension. ANN INTERN MED 139: 761-776 [Full Text]  
• Rich, S., McLaughlin, V. V. (2003). Endothelin Receptor Blockers in Cardiovascular Disease. Circulation 108: 2184-2190 [Abstract] [Full Text]  
• Sorokin, A., Kohan, D. E. (2003). Physiology and pathology of endothelin-1 in renal mesangium. Am. J. Physiol. Renal Physiol. 285: F579-F589 [Abstract] [Full Text]  
• Zonnenberg, B. A., Groenewegen, G., Janus, T. J., Leahy, T. W., Humerickhouse, R. A., Isaacson, J. D., Carr, R. A., Voest, E. (2003). Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Atrasentan: An Endothelin Receptor Antagonist for Refractory Prostate Cancer. Clin. Cancer Res. 9: 2965-2972 [Abstract] [Full Text]  
• Kenyon, K. W, Nappi, J. M (2003). Bosentan for the Treatment of Pulmonary Arterial Hypertension. The Annals of Pharmacotherapy 37: 1055-1062 [Abstract] [Full Text]  
• Nohria, A., Garrett, L., Johnson, W., Kinlay, S., Ganz, P., Creager, M. A. (2003). Endothelin-1 and Vascular Tone in Subjects With Atherogenic Risk Factors. Hypertension 42: 43-48 [Abstract] [Full Text]  
• Quaschning, T., Kocak, S., Bauer, C., Neumayer, H.-H., Galle, J., Hocher, B. (2003). Increase in nitric oxide bioavailability improves endothelial function in endothelin-1 transgenic mice. Nephrol Dial Transplant 18: 479-483 [Abstract] [Full Text]  
• Hubloue, I., Biarent, D., Kafi, S. A., Bejjani, G., Kerbaul, F., Naeije, R., Leeman, M. (2003). Endogenous endothelins and nitric oxide in hypoxic pulmonary vasoconstriction. Eur Respir J 21: 19-24 [Abstract] [Full Text]  
• Rossi, G. P., Ganzaroli, C., Cesari, M., Maresca, A., Plebani, M., Nussdorfer, G. G., Pessina, A. C. (2003). Endothelin receptor blockade lowers plasma aldosterone levels via different mechanisms in primary aldosteronism and high-to-normal renin hypertension. Cardiovasc Res 57: 277-283 [Abstract] [Full Text]  
• Jin, J. J., Nakura, J., Wu, Z., Yamamoto, M., Abe, M., Tabara, Y., Yamamoto, Y., Igase, M., Kohara, K., Miki, T. (2003). Association of Endothelin-1 Gene Variant With Hypertension. Hypertension 41: 163-167 [Abstract] [Full Text]  
• Cardillo, C., Campia, U., Bryant, M. B., Panza, J. A. (2002). Increased Activity of Endogenous Endothelin in Patients With Type II Diabetes Mellitus. Circulation 106: 1783-1787 [Abstract] [Full Text]  
• Carducci, M. A., Nelson, J. B., Kathy Bowling, M., Rogers, T., Eisenberger, M. A., Sinibaldi, V., Donehower, R., Leahy, T. L., Carr, R. A., Isaacson, J. D., Janus, T. J., Andre, A., Hosmane, B. S., Padley, R. J. (2002). Atrasentan, an Endothelin-Receptor Antagonist for Refractory Adenocarcinomas: Safety and Pharmacokinetics. JCO 20: 2171-2180 [Abstract] [Full Text]  
• Martin, P., Ninio, D., Krum, H. (2002). Effect of Endothelin Blockade on Basal and Stimulated Forearm Blood Flow in Patients With Essential Hypertension. Hypertension 39: 821-824 [Abstract] [Full Text]  
• Cardillo, C., Campia, U., Kilcoyne, C. M., Bryant, M. B., Panza, J. A. (2002). Improved Endothelium-Dependent Vasodilation After Blockade of Endothelin Receptors in Patients With Essential Hypertension. Circulation 105: 452-456 [Abstract] [Full Text]  
• Asai, T., Ohkubo, T., Katsuya, T., Higaki, J., Fu, Y., Fukuda, M., Hozawa, A., Matsubara, M., Kitaoka, H., Tsuji, I., Araki, T., Satoh, H., Hisamichi, S., Imai, Y., Ogihara, T. (2001). Endothelin-1 Gene Variant Associates With Blood Pressure in Obese Japanese Subjects: The Ohasama Study. Hypertension 38: 1321-1324 [Abstract] [Full Text]  
• Quaschning, T., Ruschitzka, F., Niggli, B., Lunt, C. M. B., Shaw, S., Christ, M., Wehling, M., Luscher, T. F. (2001). Influence of aldosterone vs endothelin receptor antagonism on renovascular function in liquorice-induced hypertension. Nephrol Dial Transplant 16: 2146-2151 [Abstract] [Full Text]  
• Cowburn, P.J., Cleland, J.G.F. (2001). Endothelin antagonists for chronic heart failure: do they have a role?. Eur Heart J 22: 1772-1784  
• Diamanti-Kandarakis, E., Spina, G., Kouli, C., Migdalis, I. (2001). Increased Endothelin-1 Levels in Women with Polycystic Ovary Syndrome and the Beneficial Effect of Metformin Therapy. J. Clin. Endocrinol. Metab. 86: 4666-4673 [Abstract] [Full Text]  
• Kotelevtsev, Y., Webb, D. J (2001). Endothelin as a natriuretic hormone: the case for a paracrine action mediated by nitric oxide. Cardiovasc Res 51: 481-488 [Full Text]  
• Pearl, J. M., Nelson, D. P., Wagner, C. J., Lombardi, J. P., Duffy, J. Y. (2001). Endothelin receptor blockade reduces ventricular dysfunction and injury after reoxygenation. Ann. Thorac. Surg. 72: 565-570 [Abstract] [Full Text]  
• Haylor, J. L., Morcos, S. K. (2001). An oral ETA-selective endothelin receptor antagonist for contrast nephropathy?. Nephrol Dial Transplant 16: 1336-1337 [Full Text]  
• Ruschitzka, F., Quaschning, T., Noll, G., deGottardi, A., Rossier, M. F., Enseleit, F., Hurlimann, D., Luscher, T. F., Shaw, S. G. (2001). Endothelin 1 Type A Receptor Antagonism Prevents Vascular Dysfunction and Hypertension Induced by 11{beta}-Hydroxysteroid Dehydrogenase Inhibition : Role of Nitric Oxide. Circulation 103: 3129-3135 [Abstract] [Full Text]  
• Liu, J.-L., Pliquett, R. U., Brewer, E., Cornish, K. G., Shen, Y.-T., Zucker, I. H. (2001). Chronic endothelin-1 blockade reduces sympathetic nerve activity in rabbits with heart failure. Am. J. Physiol. Regul. Integr. Comp. Physiol. 280: R1906-R1913 [Abstract] [Full Text]  
• Spieker, L. E., Noll, G., Ruschitzka, F. T., Luscher, T. F. (2001). Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future?. J Am Coll Cardiol 37: 1493-1505 [Abstract] [Full Text]  
• Ivy, D. D., McMurtry, I. F., Yanagisawa, M., Gariepy, C. E., Le Cras, T. D., Gebb, S. A., Morris, K. G., Wiseman, R. C., Abman, S. H. (2001). Endothelin B receptor deficiency potentiates ET-1 and hypoxic pulmonary vasoconstriction. Am. J. Physiol. Lung Cell. Mol. Physiol. 280: L1040-L1048 [Abstract] [Full Text]  
• Duru, F., Barton, M., Luscher, T. F., Candinas, R. (2001). Endothelin and cardiac arrhythmias: do endothelin antagonists have a therapeutic potential as antiarrhythmic drugs?. Cardiovasc Res 49: 272-280 [Abstract] [Full Text]  
• Elijovich, F., Laffer, C. L., Amador, E., Gavras, H., Bresnahan, M. R., Schiffrin, E. L. (2001). Regulation of Plasma Endothelin by Salt in Salt-Sensitive Hypertension. Circulation 103: 263-268 [Abstract] [Full Text]  
• MacCarthy, P. A., Pegge, N. C., Prendergast, B. D., Shah, A. M., Groves, P. H. (2001). The physiological role of endogenous endothelin in the regulation of human coronary vasomotor tone. J Am Coll Cardiol 37: 137-143 [Abstract] [Full Text]  
• Luscher, T. F., Barton, M. (2000). Endothelins and Endothelin Receptor Antagonists : Therapeutic Considerations for a Novel Class of Cardiovascular Drugs. Circulation 102: 2434-2440 [Abstract] [Full Text]  
• Ungvari, Z., Koller, A. (2000). Endothelin and Prostaglandin H2/Thromboxane A2 Enhance Myogenic Constriction in Hypertension by Increasing Ca2+ Sensitivity of Arteriolar Smooth Muscle. Hypertension 36: 856-861 [Abstract] [Full Text]  
• Ergul, A. (2000). Hypertension in Black Patients : An Emerging Role of the Endothelin System in Salt-Sensitive Hypertension. Hypertension 36: 62-67 [Abstract] [Full Text]  
• Bohlender, J., Gerbaulet, S., Kramer, J., Gross, M., Kirchengast, M., Dietz, R. (2000). Synergistic Effects of AT1 and ETA Receptor Blockade in a Transgenic, Angiotensin II-Dependent, Rat Model. Hypertension 35: 992-997 [Abstract] [Full Text]  
• Wu, S.-Q., Hopfner, R. L, McNeill, J.R., Wilson, T. W, Gopalakrishnan, V. (2000). Altered paracrine effect of endothelin in blood vessels of the hyperinsulinemic, insulin resistant obese Zucker rat. Cardiovasc Res 45: 994-1000 [Abstract] [Full Text]  
• Lambert, E., Lambert, G., Fassot, C., Friberg, P., Elghozi, J.-L. (2000). Subarachnoid hemorrhage induced sympathoexcitation arises due to changes in endothelin and/or nitric oxide activity. Cardiovasc Res 45: 1046-1053 [Abstract] [Full Text]  
• Schweda, F., Blumberg, F. C., Schweda, A., Kammerl, M., Holmer, S. R., Riegger, G. A. J., Pfeifer, M., Kramer, B. K. (2000). Effects of chronic hypoxia on renal renin gene expression in rats. Nephrol Dial Transplant 15: 11-15 [Abstract] [Full Text]  
• Ghiadoni, L., Virdis, A., Magagna, A., Taddei, S., Salvetti, A. (2000). Effect of the Angiotensin II Type 1 Receptor Blocker Candesartan on Endothelial Function in Patients With Essential Hypertension. Hypertension 35: 501-506 [Abstract] [Full Text]  
• Ono, K., Matsumori, A., Shioi, T., Furukawa, Y., Sasayama, S. (1999). Contribution of Endothelin-1 to Myocardial Injury in a Murine Model of Myocarditis : Acute Effects of Bosentan, an Endothelin Receptor Antagonist. Circulation 100: 1823-1829 [Abstract] [Full Text]  
• Taddei, S., Virdis, A., Ghiadoni, L., Sudano, I., Notari, M., Salvetti, A. (1999). Vasoconstriction to Endogenous Endothelin-1 Is Increased in the Peripheral Circulation of Patients With Essential Hypertension. Circulation 100: 1680-1683 [Abstract] [Full Text]  
• Prendergast, B, Newby, D E, Wilson, L E, Webb, D J, Mankad, P S (1999). Early therapeutic experience with the endothelin antagonist BQ-123 in pulmonary hypertension after congenital heart surgery. Heart 82: 505-508 [Abstract] [Full Text]  
• Schiffrin, E. L. (1999). Role of Endothelin-1 in Hypertension. Hypertension 34: 876-881 [Abstract] [Full Text]  
• Weber, C., Gasser, R., Hopfgartner, G. (1999). Absorption, Excretion, and Metabolism of the Endothelin Receptor Antagonist Bosentan in Healthy Male Subjects. Drug Metab. Dispos. 27: 810-815 [Abstract] [Full Text]  
• Nishikibe, M., Ohta, H., Okada, M., Ishikawa, K., Hayama, T., Fukuroda, T., Noguchi, K., Saito, M., Kanoh, T., Ozaki, S., Kamei, T., Hara, K., William, D., Kivlighn, S., Krause, S., Gabel, R., Zingaro, G., Nolan, N., O'Brien, J., Clayton, F., Lynch, J., Pettibone, D., Siegl, P. (1999). Pharmacological Properties of J-104132 (L-753,037), a Potent, Orally Active, Mixed ETA/ETB Endothelin Receptor Antagonist. J. Pharmacol. Exp. Ther. 289: 1262-1270 [Abstract] [Full Text]  
• Berthold, H., Munter, K., Just, A., Kirchheim, H. R., Ehmke, H. (1999). Stimulation of the Renin-Angiotensin System by Endothelin Subtype A Receptor Blockade in Conscious Dogs. Hypertension 33: 1420-1424 [Abstract] [Full Text]  
• OTTOSSON-SEEBERGER, A., AHLBORG, G., HEMSÉN, A., LUNDBERG, J. M., ALVESTRAND, A. (1999). Hemodynamic Effects of Endothelin-1 and Big Endothelin-1 in Chronic Hemodialysis Patients. J. Am. Soc. Nephrol. 10: 1037-1044 [Abstract] [Full Text]  
• Tiret, L., Poirier, O., Hallet, V., McDonagh, T. A., Morrison, C., McMurray, J. J. V., Dargie, H. J., Arveiler, D., Ruidavets, J.-B., Luc, G., Evans, A., Cambien, F. (1999). The Lys198Asn Polymorphism in the Endothelin-1 Gene Is Associated With Blood Pressure in Overweight People. Hypertension 33: 1169-1174 [Abstract] [Full Text]  
• Nelson, J. B., Opgenorth, T. J., Fleisher, L. A., Frank, S. M. (1999). Perioperative Plasma Endothelin-1 and Big Endothelin-1 Concentrations in Elderly Patients Undergoing Major Surgical Procedures. Anesth. Analg. 88: 898-898 [Abstract] [Full Text]  
• Rossi, G. P., Colonna, S., Pavan, E., Albertin, G., Della Rocca, F., Gerosa, G., Casarotto, D., Sartore, S., Pauletto, P., Pessina, A. C. (1999). Endothelin-1 and Its mRNA in the Wall Layers of Human Arteries Ex Vivo. Circulation 99: 1147-1155 [Abstract] [Full Text]  
• Tsutamoto, T., Wada, A., Hisanaga, T., Maeda, K., Ohnishi, M., Mabuchi, N., Sawaki, M., Hayashi, M., Fujii, M., Kinoshita, M. (1999). Relationship between endothelin-1 extraction in the peripheral circulation and systemic vascular resistance in patients with severe congestive heart failure. J Am Coll Cardiol 33: 530-537 [Abstract] [Full Text]  
• Cardillo, C., Kilcoyne, C. M., Waclawiw, M., Cannon, R. O. III, Panza, J. A. (1999). Role of Endothelin in the Increased Vascular Tone of Patients With Essential Hypertension. Hypertension 33: 753-758 [Abstract] [Full Text]  
• Emoto, N., Nurhantari, Y., Alimsardjono, H., Xie, J., Yamada, T., Yanagisawa, M., Matsuo, M. (1999). Constitutive Lysosomal Targeting and Degradation of Bovine Endothelin-converting Enzyme-1a Mediated by Novel Signals in Its Alternatively Spliced Cytoplasmic Tail. J. Biol. Chem. 274: 1509-1518 [Abstract] [Full Text]  
• Takeda, Y., Miyamori, I., Furukawa, K., Inaba, S., Mabuchi, H. (1999). Mechanisms of FK 506–Induced Hypertension in the Rat. Hypertension 33: 130-136 [Abstract] [Full Text]  
• Blezer, E. L. A., Nicolay, K., Goldschmeding, R., Jansen, G. H., Koomans, H. A., Rabelink, T. J., Joles, J. A. (1999). Early-Onset But Not Late-Onset Endothelin-A–Receptor Blockade Can Modulate Hypertension, Cerebral Edema, and Proteinuria in Stroke-Prone Hypertensive Rats. Hypertension 33: 137-144 [Abstract] [Full Text]  
• Strachan, F. E., Spratt, J. C., Wilkinson, I. B., Johnston, N. R., Gray, G. A., Webb, D. J. (1999). Systemic Blockade of the Endothelin-B Receptor Increases Peripheral Vascular Resistance in Healthy Men. Hypertension 33: 581-585 [Abstract] [Full Text]  
• Sutsch, G., Kiowski, W., Yan, X.-W., Hunziker, P., Christen, S., Strobel, W., Kim, J.-H., Rickenbacher, P., Bertel, O. (1998). Short-Term Oral Endothelin-Receptor Antagonist Therapy in Conventionally Treated Patients With Symptomatic Severe Chronic Heart Failure. Circulation 98: 2262-2268 [Abstract] [Full Text]  
• Borcsok, I., Schairer, H. U., Sommer, U., Wakley, G. K., Schneider, U., Geiger, F., Niethard, F. U., Ziegler, R., Kasperk, C. H. (1998). Glucocorticoids Regulate the Expression of the Human Osteoblastic Endothelin A Receptor Gene. J. Exp. Med. 188: 1563-1573 [Abstract] [Full Text]  
• Graido-Gonzalez, E., Doherty, J. C., Bergreen, E. W., Organ, G., Telfer, M., McMillen, M. A. (1998). Plasma Endothelin-1, Cytokine, and Prostaglandin E2 Levels in Sickle Cell Disease and Acute Vaso-Occlusive Sickle Crisis. Blood 92: 2551-2555 [Abstract] [Full Text]  
• Moreau, P. (1998). Endothelin in hypertension: A role for receptor antagonists?. Cardiovasc Res 39: 534-542 [Abstract] [Full Text]  
• Rabelink, T. J, Stroes, E. S.G, Bouter, K.P., Morrison, P. (1998). Endothelin blockers and renal protection: a new strategy to prevent end-organ damage in cardiovascular disease?. Cardiovasc Res 39: 543-549 [Full Text]  
• Kirchengast, M., Munter, K. (1998). Endothelin and restenosis. Cardiovasc Res 39: 550-555 [Full Text]  
• Geny, B., Piquard, F., Lonsdorfer, J., Haberey, P. (1998). Endothelin and heart transplantation. Cardiovasc Res 39: 556-562 [Full Text]  
• Haynes, W. G., Ferro, C. J., Webb, D. J., Kramer, B. K., Schweda, F., Riegger, G. A.J., Krum, H., Lacourciere, Y., Charlon, V. (1998). Bosentan in Essential Hypertension. NEJM 339: 346-347 [Full Text]  
• (1998). Endothelin-Receptor Antagonist for Hypertension. Journal Watch Cardiology 1998: 8-8 [Full Text]